Using Dose-Response Correlation Re-Analyzing to Distinguish Placebo from Standardized Rose-Hip Powder (Lito) in a Clinical Trial on Osteoarthritis Where Data Initially Looked Identical.

Both active and placebo groups showed large, statistically significant improvements exceeding 50% in WOMAC pain and function, with no statistically significant differences between groups in standard comparisons.

• Study was a multicenter, double-blind, randomized, placebo-controlled trial with N = 120 participants with hip and knee osteoarthritis (ClinicalTrials.gov NCT01459939).
• Both groups showed significant improvement 'over 50%' in WOMAC pain and function scores.
• Standard between-group comparisons found no statistically significant differences between active and placebo groups at 6 or 12 weeks.
• The large placebo response rendered conventional between-group analysis unable to detect treatment effects.

Only the active Rosa-canina group showed a consistent negative correlation between body weight and symptom improvement, indicating a dose-response relationship at both 6 and 12 weeks.

• Pearson correlations were calculated between dose per kg body weight and changes in WOMAC pain and function separately for active and placebo groups.
• The negative correlation indicates that participants with lower body weight (receiving higher mg/kg dose) experienced greater improvement.
• This dose-response relationship was observed at both 6-week and 12-week time points in the active group.
• No such dose-response relationship was observed in the placebo group at either time point.

Weight-stratified plots revealed an exposure-response gradient in the active treatment group that was absent in the placebo group.

• Because participants received fixed doses, variability in mg/kg exposure arose naturally from differences in individual body weights.
• Weight-stratified plots were used to visualize the exposure-response relationship.
• The gradient was present only in the active group, consistent with a pharmacologically active effect of the rose-hip preparation.
• This approach served as a secondary analysis of the original randomized controlled trial data.

The dose-response correlation method distinguished genuine active treatment effects from placebo responses in a trial where standard analyses had failed to do so.

• The method exploits naturally occurring variability in mg/kg exposure due to differing body weights when a fixed dose is administered.
• Authors describe the method as 'low-cost, easy-to-implement.'
• The findings are described as 'consistent with findings from earlier rose-hip research.'
• Authors propose that incorporating such analyses 'could improve the identification of nutrients containing biologically active preparations and support dose selection in future clinical research.'

Large positive placebo responses are identified as a major methodological challenge in clinical trials evaluating food supplements and nutrients.

• The paper states that 'large positive responses to placebo are common in clinical trials and pose a major challenge when evaluating different treatments, including new foods.'
• Standard between-group comparisons 'may fail to detect true effects when placebo improvements are significant.'
• The osteoarthritis trial context is noted as particularly susceptible to large nonspecific improvements.
• The authors frame dose-response correlation analysis as a solution to this specific methodological problem.